Phase 3 study of IV lasmiditan in migraine patients

Trial Profile

Phase 3 study of IV lasmiditan in migraine patients

Planning
Phase of Trial: Phase III

Latest Information Update: 17 May 2016

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Acronyms RANGER
  • Most Recent Events

    • 17 May 2016 New trial record
    • 11 May 2016 According to CoLucid Pharmaceuticals media release, company has filed an Investigational New Drug application (IND) with the FDA for IV lasmiditan and the company's clinical program may proceed when it manufactures its IV product under the FDA's current Good Manufacturing Practices (cGMP) and it submits a certificate of analysis (COA). Company has also received preliminary feedback on this trial and will be resubmitted under a request for SPA in parallel to the submission of the COA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top